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Alzheimer's disease (AD) is a debilitating and degenerative dementia with a 
senile onset (over 65 years, but can occur even in the presenile age - before 
age 65). In 1906, Aloise Alzheimer, a German psychiatrist, identified and 
presented the first case of what became known as Alzheimer's disease in a 
fifty-year-old woman called Auguste D. 
In this report, he underlined several cardinal features of the disorder that are 
currently observed in most patients: progressive memory impairment, 
disordered cognitive functions, altered behavior including paranoia, 
delusions, and loss of social appropriateness and a progressive decline in 
language function. 
In the early stages of AD, the most commonly recognized symptom is 
inability to acquire new memories, such as difficulty in recalling recently 
observed facts. Gradually, bodily functions are lost, ultimately leading to 
death. Individual prognosis is difficult to assess, and the duration of the 
disease varies. AD develops for an indeterminate period of time before 
becoming clinically apparent, and it can progress undiagnosed for years. In 
fact, the cause and progression of Alzheimer's disease are not well 
understood. When AD is suspected, the diagnosis is usually confirmed by 
behavioral assessments and cognitive tests, often followed by a brain scan. 
An internationally agreement upon standard of TEST for clinical diagnosis 
of AD includes a detailed history, functional measurement of decline such 
as instrumental activity of daily living scales, mini mental status 
examination tests (MMSE), Clinical Dementia Rating (CDR), Disability 
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Assessment for Dementia (DAD), neuropsychological evaluation, 
neurological and psychiatric examination. 
The MMSE test, for example, allows to classify subjects with dementia 
according to categories of clinical severity and to the rate of cognitive 
decline. This test, developed by Folstein in 1975, is widely used, since it 
allows a semi quantitative evaluation of the degree of cognitive impairment 
(Folstein MF et al., 1975). 
The cognitive evaluation obtained from these test is today accurate and 
reached up to 90% of the confirmed autopsy cases. AD must be 
differentiated from other causes of dementia: vascular dementia, dementia 
with Lewy bodies, Parkinson‟s disease with dementia, frontotemporal 
dementia, and reversible dementias. 
An intermediate stage between normal ageing and dementia has long been 
recognized by several classification systems and these attempts have viewed 
the condition as either physiological ageing or the beginnings of a 
pathological process and has now defined as mild cognitive impairment 
(MCI) (DeCarli C, 2003). 
Originally, MCI diagnosis required the presence of memory complaint 
(preferably corroborated by an informant), objective memory impairment 
for age, preserved general cognitive function, normal functional activities, 
and no dementia. The impact of MCI is different in a high functioning 
professional aged 55 to a retired 80 year old with few cognitive demands in 
their life. 
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Because not all individuals with MCI progress to clinical dementia, it is 
critical to identify risk factors and biomarkers for the development of 
dementia and AD in this cohort. Toward this end, Aggarwal et al. showed 
that possession of the ε4 variant of the allele for apolipoprotein E (APOE), a 
known risk factor for the development of AD in normal elderly individuals, 
is also associated with increased risk of developing AD in individuals with 
MCI (Aggarwal NT et al., 2005). 
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Epidemiology of Alzheimer’s disease 
AD is now a worldwide spread disease, as the incidence of AD increases 
with age, it is particularly important to consider the mean age of the 
population of interest. In the United States, Alzheimer‟s disease prevalence 
was estimated to be 1.6% in 2000 both overall and in the 65–74 age group, 
with the rate increasing to 19% in the 75–84 group and up to 42% in the 
older than 84 year group (Hebert LE et al., 2003). 
Another study estimated that 
in 2006, 0.40% of the world 
population (absolute number 
26.6 million, range 11.4–59.4 
million) would be afflicted by 
AD, that the prevalence rate 
would triple and the absolute 
number would quadruple by 2050 (Brookmeyer R et al., 2007). 
In Italy, AD affected subjects are between 800.000 and 1 million and 
unfortunately the number of new cases/year (incidence) is going to 
dramatically increase as a consequence of the progressive increase of the 
mean age and life expectancy in our population. In Fig 1 the increasing 
number of Italian subjects affected by Alzheimer‟s disease during the last 10 
years and the projection of the incidence for the next 40 years are shown. 
 
Figure 1: Estimated number of people with AD in 
Italy in 1991, 1999, 2020 and 2050 
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Pathogenesis of Alzheimer’s Disease 
Alzheimer‟s disease is a heterogeneous multifactorial and progressive 
neurodegenerative disease that affects specific areas of the brain. The neuro-
pathological hallmarks of the disease are: neuritic senile plaques, 
neurofibrillary tangles, neuronal atrophy and cortical neurodegeneration 
(Terry RD, 1994) AD begins in the 
entorhinal cortex, a brain region 
that is near the hippocampus and 
has direct connections to it. Healthy 
neurons in this region begin to 
work less efficiently, lose their 
ability to communicate, and 
ultimately die. This process 
gradually spreads to the hippocampus, the brain region that plays a major 
role in learning and is involved in converting short-term memories to long-
term memories. Finally, affected regions begin to atrophy. 
Senile Plaques 
Senile plaques (Fig. 3), with diameters between 10 and 200μm, are 
extracellular deposits of amyloid in the gray matter of the brain. The 
deposits are associated with degenerative neural structures and an 
abundance of microglia and astrocytes (Mancardi GL et al., 1983; McGeer 
 
 
Figure 2: Specific areas of the brain mainly 
affected by AD 
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PL et al., 1993). These plaque have been identified in several AD brain 
areas like hippocampus, amygdale and in brain cortex. 
Beta amyloid peptide (Aβ) is the main component of senile plaques: Aβ is a 
short peptide of 40-42 amino acids and with a molecular weight of 4.2kDa. 
Moreover, amyloid filaments are able to be folded in a beta sheet structure 
(McLean C and Beureuthe K, 1997). 
Aβ peptide derives 
from a precursor 
protein molecule 
named Amyloid 
precursor protein or 
APP that undergoes 
to an abnormal 
processing. 
Senile plaques are surrounded also by other molecules present in minor 
amounts such as cytokines, apolipoprotein E and inflammatory molecules 
Neurofibrillary tangles (NFT) 
NFT (Fig. 4) are a major microscopic lesion of AD and are located 
primarily in large pyramidal neurons of Ammon‟s horn and the cerebral 
neocortex, although neurofibrillary pathology is also encountered in deep 
structures, including midbrain and pontine tegmentum, basal nucleus of 
Meynert, and hypothalamus (Braak H and Braak E, 1991). 
 
Figure 3: Senile plaques in affected AD brain 
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Morphologically, NFT are classically described as consisting of numerous 
paired helical filaments (PHF), (Kidd M, 1963) which are composed of 2 
axially opposed helical filaments with a diameter of 10 nm and a half-period 
of 80 nm (Wisniewski HM et al., 1964). 
Healthy neurons have an 
internal “bone” performed 
by microtubular structures; 
these structures are mainly 
composed and stabilized 
by tau protein. 
In Alzheimer‟s disease, 
this protein is not in a 
normal conformation: tau protein results in an iper phosphorilated form and 
this implies a grater probability of self annealing of tau units (Buèe L et al., 
2000). This abnormal annealing of tau protein causes a degeneration of 
microtubular structure and compromise axonal transport resulting in a very 
instable conditions where neurons are no longer able to communicate in an 
optimal manner. 
 
 
Figure 4: Neurofibrillary tangles in affected AD brain 
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Pathogenetic hypothesis 
Alzheimer‟s disease is a very complex and a multifactorial disease in which 
intrinsic, genetic and environmental factor interact with each other and 
contribute to the onset of the disease. 
A large number of hypothesis and theories have been proposed to explain all 
the processes and the mechanisms leading to the pathogenesis and the onset 
of the disease. For example amyloid hypothesis, inflammatory hypothesis, 
vascular hypothesis, viral hypothesis. 
Amyloid hypothesis 
Classical pathological features of AD are the presence of senile plaques and 
neurofibrillary tangles in SNC. The main component of senile plaques is the 
β amyloid peptide resulting from a proteolitic cut of the amyloid precursor 
protein (APP). APP is the Aβ peptide precursor and is a trans-membrane 
glycoprotein widely expressed (it is also present on platelets), produced by 
the endoplasmatic reticulum and involved in the neuronal and dendritic 
growth and synapses formation. 
The metabolic cleavage of APP involves three different enzymes called α, β 
and  secretase. The membrane protein α-secretase is the first enzyme that 
cleaves βAPP molecule between residues Lys687 and Leu688; in this way a 
small peptide remains anchored to the membrane (αCTF) and a soluble N-
Ter peptide (sAPPα) is released in the extracellular compartment. Proteolitic 
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cleavage by α secretase prevents Aβ release and results in the so called non 
amyloidogenic pathway (Thinakaran G and Koo EH, 2008). 
On the other hand, the combined and sequential cleavage on APP by β and 
secretases releases Aβ peptide composed of 40-42 aminoacids. β secretase 
(called also BACE) in fact cuts βAPP molecule between residues Met 671 
and Asp672 residues; two fragments are generated: a βCTF, linked to the 
membrane and a N-Ter peptide named sAPPβ. The trans-membrane 
fragment becomes substrate for the γ secretase enzyme that produces 
different small peptides (Aβ 40/42/43) resulting by Ile712, Tnr 714 e Val 
715 cleavage. 
βA 40-42 peptide, synthesized mainly in the endhoplasmatic reticulum and 
in Golgi system are majar form of Aβ produced during βAPP metabolism. 
In the pathogenesis of AD, accumulation of Aß in the brain, particularly 
Aß42, is considered to be an important step (Small DH and McLean CA, 
1999). Aß40 is the major form of secreted Aß. However, Aß42, the minor 
form, aggregates more readily and is thought to seed amyloid fibril 
polymerization during the early stages of plaque formation (Jarrett TJ et al., 
1993). Amyloid aggregates form insoluble filaments that are about 7-9 nm 
in diameter. The fibrillar forms of Aß, ß-pleated amyloid fibrils, consist of 
antiparallel-pleated sheets, thought to be especially neurotoxic. 
Understanding how and where Aß aggregation begins may elucidate the 
mechanism of AD pathogenesis. Recent reports suggest that Aß is generated 
and accumulates intracellularly (Turner RS et al., 1996; Skovronsky DM et 
al., 1998; Gouras JK et al., 2000). It has also been reported that 
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intraneuronal accumulation of Aß peptides may precede the detection of 
extracellular amyloid plaques and NFTs (Gouras JK et al., 2000), and that 
this may be associated with neurodegeneration (Chui DH et al., 1999). 
Masliah et al. showed by electron microscopy that neuronal processes near 
plaques can display fine intracellular amyloid fibrils adjacent to rough ER 
and coated vesicles (Masliah E et al., 1996). Recent evidence suggests that 
neurotoxic effects of Aß may be independent of plaque formation in vivo 
(Hsia AY et al., 1999; Chui DH et al., 1999) and independent of ß-pleated 
Aß formation in vitro (Lambert JC et al., 1998; Hartley DM et al., 1999; 
Walsh DM et al., 1999). 
Inflammatory hypothesis 
The hypothesis that inflammation may participate in Alzheimer's disease 
pathogenesis was first articulated about 20 years ago, and despite two 
decades of work, many of the central questions regarding the inflammatory 
response in the Alzheimer's disease brain remain unanswered ( 
One of the hypothesis is that the presence of amyloid plaques and 
neurofibrillary tangles may stimulate a chronic inflammatory reaction to 
clear this debris. 
Inflammatory response is a very complex process, slightly regulated that 
involves the synthesis and the release of numerous factors such as 
cytokines, inflammatory mediators, histamine, prostaglandine and also some 
hormones (McGeer EG and McGeer PL, 1998). 
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In AD brain, in fact, inflammatory response appears to be alterated: high 
levels of cytokines as Tumor Necrosis Factor (TNF), Interleukin-1 (IL-1), 
IL-6, IL-8 IL-10 and some interferon seems to be elevated (Baumann H and 
Gauldie J, 1994). A recent report showed that alpha 1 antichymotrypsin 
(ACT) levels were higher in AD patients than in CIND (cognitive 
impairment but not dementia) or in controls (Porcellini E, et al 2008). 
In addition pro-inflammatory cytokines enhance A40 and A42 peptides 
production and inhibit amyloid precursor protein (APP) production, on the 
whole and especially the soluble fraction of APP with neuronal protective 
effect. 
Astrocytes and microglia have a pivotal role in the inflammatory activation. 
Astocytes represent about the 40% of the total population of the CNS and 
are involved in important brain functions such as the regulation of neuronal 
growth and are able to repair to neuronal damages. 
In AD brain astrocytes have been found associated to β amyloid plaques 
(Norenberg MD., 1994; Masliah E et al., 2000). 
Astrocites produce a large number of citokines as IL-1 (Griffin WS, 1989), 
IL-6 (Bauer J, 1992), TNF (Sawada M, 1989) and alpha 1 antichymotrypsin 
(ACT) that might have a pivotal role in AD pathogenesis since they could 
modify the normal metabolism of APP pathway (Goldgaber D, 1989; 
Altstiel LD, 1991). 
In fact, many Authors have demonstrated that in Alzheimer‟s disease, 
several of inflammatory molecules and cytokines are increased. A recent 
report showed that ACT levels were higher in AD patients than in CIND 
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(cognitive impairment but not dementia) or controls (Porcellini E et al., 
2008). 
Also microglia is located inside the neuropathological lesions associated to 
AD. These cells are phenotipically similar to blood monocytes and tissue 
macrophages and replace their functions in the brain (Ransohoff RM and 
Perry VH, 2009). Microglial cell expose on their surface complement 
receptors, MHC I and MHC II molecules and release cytokines and 
molecules involving in acute phase inflammation. 
Microglia, such as astrocytes, have a double role in the cellular response 
against neuronal damage: one pathogenetic function of promoting 
inflammation promoter and a protective role (Gonzales-Scarano F et al., 
1999). 
Anyhow, it is not clear whether inflammation in AD is an early event or a 
secondary process inducted by a pre existing damage. 
The importance of inflammation in AD is further strengthened by 
epidemiological data showing that the routine use of the non-steroid anti-
inflammatory drugs (NSAIDs) was associated with a decreased incidence of 
AD (Breitner JC et al., 1994.; In‟t Veld BA et al., 2001). 
Moreover, molecular genetic studies have indicated also that single 
nucleotide polymorphisms (SNPs) located in inflammatory genes could be 
linked to Alzheiemer disease (Licastro et al., 2007). These SNPs may act 
both as risk and/or protective factors for the disease. 
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Vascular Hypothesis 
The vascular hypothesis of Alzheimer disease, first proposed by De La torre 
in 1993, provides substantial evidence that suggests vascular risk factors 
(VRF) play a critical role in the development of cognitive decline and AD 
during aging (de la Torre JC and Mussivand T, 1993). 
There are many notable observational epidemiological studies that have 
helped to clarify the role of vascular risk factors for AD; these include the 
Honolulu Asia Aging Study, the Goteborg Study ,and the Frammingam 
Study. All these investigations have underlined the possible role of 
hypertension, diabetes, smoking, lipids homocysteine, physical inactivity, 
fat intake, systemic marker of atherosclerosis and other vascular factors that 
may be associated with increasing or decreasing risk of cognitive 
impairment and AD. Moreover, several studies suggest an important role for 
blood vessels alterations in the pathogenesis of AD dementia (Skoog I et al., 
1996; Hofman A et al., 1997; Snowdon DA et al., 1997) 
Numerous structural and functional abnormalities of the cerebro-
microvasculature in AD have been also identified, (de la Torre JC and 
Mussivand T, 1993; Kalaria RN, 1996) including decreased microvascular 
density and vascular distortions such as vessel kinking, twisting, tortuosity, 
and looping. In addition, several active functions of the blood-brain barrier, 
including glucose transport, are diminished in AD. Furthermore, AD brain 
vessels are oxidatively damaged, express inflammatory mediators, and over-
produce nitric oxide. (Dorheim MA et al., 1994). Elevated vascular 
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production of nitric oxide, derivatives with potential neurotoxin action, 
could contribute to neuronal injury and death in AD. 
We have just discussed that results of epidemiological studies suggest that 
chronic use of certain drugs (NSAIDs) significantly decreases the risk of 
Alzheimer‟s disease (Breitner JC et al., 1994.; In‟t Veld BA et al., 2001). 
Also if brain inflammation has became a major focus for Alzheimer‟s 
disease research, brain inflammation cannot, however, explains the risk 
reduction conferred by drugs that may lack substantial anti-inflammatory 
activity. Some putative Alzheimer‟s disease preventive drugs, such 
lovastatin, pravastatin, H2 antagonist, aspirin, also inhibit angiogenesis. 
These observations have led to consider again the role of the brain vascular 
endothelial cells in the pathogenesis of the disease. 
Endothelial cells in fact could respond to both hypoxia and inflammation by 
regulating angiogenesis response. Brain angiogenesis is a tightly controlled 
process that requires chemotactic, proteolytic and mitogenic activities of the 
endothelial cells (Plate KH, 1999). For instance an increasing expression of 
vascular endothelial growth factor (VEGF), transforming growth factor b 
(TGFb) and tumor necrosis factor a (TNFa) may control angiogenesis in the 
brain (Tarkowsky E et al., 2002) 
Ultrastructural studies have shown that β-amyloid plaques are closely 
associated with brain microvessels, and that Alzheimer's disease brain 
capillaries contain preamyloid deposits (Miyakawa T, 1997) Furthermore 
the β-amyloid plaque generates reactive oxygen species that damage brain 
endothelium (Liu F et al., 2000). 
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Progressive deposition of amyloid precursor protein leads to accumulation 
of the β-amyloid plaque, which generates more reactive oxygen species and 
further induces endothelial damage. By this way endothelial-dependent 
events may contribute to β-amyloid accumulation in the brain of patients 
with Alzheimer's disease and neuronal death (Vagnucci A, 2003) 
Viral Hypothesis 
Alzheimer‟s disease is the leading cause of dementia in developed countries. 
Its etiology is recognized as multifactorial, with the possible inclusion of 
infectious agents. In the 1960s and 1970s, researchers observed elevated 
levels of antibodies to herpes simplex virus type 1 (HSV-1) in patients with 
psychiatric disorders (Cleobury JF et al., 1971; Lycke E et al., 1974). 
On the basis of these results, Sequiera et al, studied HSV-1 nucleic-acid 
sequenze in the brain of demented and psychiatric patients (Sequiera LW et 
al., 1979) and found that the HSV-1 genome was present in brain samples of 
elderly patients with dementia. 
HSV-1 was found in both AD and normal aged brains (Jamieson GA et al., 
1991; Jamieson GA et al., 1992; Wozniak MA et al., 2005). 
The association of virus, in particular herpes virus, with AD, could be 
involved for several reason: 
1) in acute HSV-1 encephalitis, infection targets particular regions, 
including hippocampus and the frontal and temporal cortices, which 
are also prominently affected in AD (Denaro FJ et al., 2003) 
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2) viral DNA has been found in the same regions as those most affected 
in AD (Honjo K et al., 2009) 
3) HSV-1 DNA was detected in only a very small proportion of brains 
from younger people, indicating that the virus can enter the brain 
when an individual becomes older, perhaps because of the age related 
decline of the immune system (Wozniak MA et al. 2005) 
A recent pubblication on 
Nature Genetics (Lambert 
et al. 2009) about a 
Genome Wide 
Association (GWA) 
showed indeed, that a 
genetic cluster on 
chromosome 19 was 
strongly associated with 
Alzheimer‟s disease. All 
these genes were located near APOE gene, the main gene associated to 
sporadic AD. The first set of genes was located in close vicinity of the 
APOE locus on the chromosome 19 (table 1) and consisted of the poliovirus 
receptor-related 2 or nectin-2 (NC-2), apolipoprotein E (APOE), the 
translocase of outer mitochondrial membrane 40 homolog (TOMM-40), 
the glycoprotein carcinoembryonic antigen related cell adhesion molecule-l6 
(CEACAM-l 6) and B-cell/lymphoma-3 (Bcl-3) genes. 
 
Table 1: genetic locus on chromosome 19 near APOE 
gene 
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These gene are involved in several viral pathway, it has been suggested that 
they result in a genetic signature that might affect individual brain 
susceptibility to infection by herpes virus family during aging, leading to 
neuronal loss, inflammation and amyloid deposition (Porcellini E et al., 
2010). 
It is likely that in genetically predisposed individuals, i.e with the above 
genetic signature, and with a defective immune response latent viruses 
might in the brain reactivated with an increased frequency and contribute to 
neuro-degenerative processes leading to cognitive impairment and AD. 
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Genetic of Alzheimer’s disease 
The vast majority of Alzheimer's disease cases are sporadic. 
This mean that there is not a dominant genetic transmission, however some 
genes may act as risk factors promoting late onset AD. On the other hand, 
about 1% of AD cases are indeed familial forms with an autosomal-
dominant inheritance; in this cases the disease has an onset before the age of 
65 years (Early onset AD). 
Familial form of early onset AD 
Three genetic locus seem to be involved in the mendelian autosomal 
dominant form of Alzheimer: 
1) Precurson β amyloid protein (APP) on chromosome 21 
2) Presenil 1 (PS1) on chromosome 14 
3) Presenilin 2 (PS2) on chromosome 1 
The mutant gene APP is located on chromosome 21. Down Syndrome (DS) 
is the consequent of the presence of an extra copy of the chromosome 21. 
DS subjects often suffer of Alzheimer and show brain alterations with 
neuropathological features similar to those of AD, but with an early onset. 
As we just mentioned before, APP is the precursor of Aβ peptide, the main 
component of senile plaques. 
It has been reported that mutations on β and γ secretase, the two enzyme 
involved in the cleavage of APP leading to Aβ formation, could be modify 
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the normal processing of APP resulting in neuronal death (Goldgaber D et 
al.,1987; Goate A, et al., 1991). 
PS1 gene is located on chromosome 14 and was identified by Rogaev in 
1995 (Rogaev EI et al., 1995). 
PS1 function is not clear and seems to be involved in the regulation of 
protein traffic and transduction signal during the development. 
60 mutations in PS1 have been identified: many of these mutation are miss-
sense mutation localized in transmembrane domain. Mutations in exon 5 
and 8 have been correlated to the age of onset of the disease (Cruts M, 
1996;). Mutations in presenilin 2 (PS2) on chromosome 1 were first 
described in 1995 and only 18 potentially pathogenic mutations have been 
reported (Levy-Lahad E et al., 1995; Rogaev EX et al., 1995). 
Recent studies have shown that the lack of PS1 and PS2 prevents the γ-
secretase cleavage; this leads to an accumulation of C-terminal fragments 
and increased production of beta-fragment amyloid that is the basis of the 
formation of amyloid plaques. In addition, PS1 and PS2 appear to be also 
targets for the cleavage of some proteins by caspases, activated during 
apoptosis and this could suggests a role for PS1 and PS2 in neuronal death. 
However, most AD cases are late onset (>65 years of age), account for the 
majority of clinical AD and do not show a clear mendelian pattern of 
segregation. Other genetic factors may also play an important role in 
determining late onset AD risk. 
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Sporadic form of late onset AD 
Complex disease, such as sporadic AD, are presumed to be the results of the 
interactions of many genes and environmental factors. Genetically, AD is an 
heterogeneous and complex disease , displaying no single or simple mode of 
inheritance. In 1994, two biochemists W. Strittmatter e G. Salvesen 
hypotized that in AD, other protein might deposit in brain plaques 
One of this protein was found to be Apolipoprotein E (ApoE) the main 
cholesterol transporter in the brain (Strittmatter WJ et al., 1994). The ApoE 
is a glycoprotein of about 299 amino acids and whose gene is located on 
chromosome 19. It is present in three different isophorm called E2, E3 and 
E4 derived form three different allelic variations: APOE ε2, ε3 e ε4. The 
combination of these three alleles leads to the identification of six different 
genotypes being the ε3/ ε3 the most frequent. These isoforms derived from 
the substitution Arg-Cys in aminoacidic residues 112 and 158. 
The apolipoprotein E ε4 allele is the only known genetic variant that has 
been constantly associated with increased late-onset AD risk. This 
association has been confirmed in a large number of study and in different 
ethnic group (Ganguli M et al., 2000). In other studies a protective effect of 
the APOE ε2 allele in AD patients has been demonstrated (Morrow JA 
1999). 
The presence of the allele ε4 predispose to an increased risk and is not by 
itself sufficient to establish the clinical diagnosis since many people with 
AD do not possess this allele (Laws M et al., 2003; Rubinsztein DC et al., 
1999). By contrast, susceptibility for late-onset AD shows less obvious or 
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no apparent familiar aggregation, and is likely to be governed by an array of 
common risk alleles across a number of different gene. These genes affect 
various pathways, many of which are likely to be involved in inflammation, 
cholesterol metabolism, -amyloid metabolism, angiogenesis, oxidative 
stress, and other less defined genes (Combarros O et al., 2002). 
In recent years, many studies have tried to clarify whether polymorphisms 
present in genes regulating inflammation or cholesterol pathway were 
correlated to a differential risk of developing AD or to a different rate of 
cognitive decline. For example, Interleukin-1 (IL-1) is a cytokine involved 
in inflammation. IL-1 beta when released in the blood at high levels induces 
fever, sleep, anorexia and ipotension. This cytokine is expressed by 
activated microglia in AD (Sheng JG et al., 1996). On the promoter region 
of IL-1 beta gene is present a polymorphism at position -511 and the TT 
genotype increased the risk of AD (Licastro F et al., 2000; Chiappelli M et 
al., 2006). 
IL-10 is another inflammatory gene found associated with Alzheimer‟s 
disease. IL-10 gene, located on chromosome 1, is synthesized in central 
nervous system and its function is to limit the inflammatory response. Many 
single nucleotide polymorphism (SNP) have been identified in this gene and 
the most informative one is at position -1082, in the promoter region 
(Tagore A et al., 1999). 
Moreover, studies from our laboratory also confirmed that the presence of 
AA genotype in the promoter region of IL-10 gene increased the risk of 
developing AD and the rate of cognitive decline (Lio D et al., 2003). 
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Alpha-1 antichymotrypsin gene is localized in the chromosome 14 and 
codes for a phase acute protein. ACT is also present as secondary 
component in senile plaques and amyloid deposits (Furby A et al., 1991). 
ACT is secreted in the brain by reactive astrocytes surrounding amyloid 
plaques. High levels of ACT were present in cerebro spinal fluid and blood 
from AD patients (Licastro F et al., 1995; Morgan K et al., 2001). 
A SNP in the promoter region at the position -51 resulted strongly 
associated with AD and with an accelerated rate of cognitive deterioration 
(Licastro F et al., 2005). 
The hydroxyl-methyl-glutaryl Coenzime A reductase (HMGCR) is a gene 
coding for the limiting step enzyme of cholesterol synthesis. HMGCR is 
also the target of statins, a group of drugs that act decreasing the cholesterol 
levels (Chong PH et al., 2002) and some epidemiological studies reports a 
negative association between the statin use and AD incidence (Kuodinov 
AR et al., 1998). A polymorphism in the promoter region at position -911 
(tranversion C/A) is associated with AD and with a fast cognitive decline 
(Porcellini E et al., 2007). 
Recently, it has been suggested that AD could be an angiogenesis-dependent 
disorder (Sun Y et al. 2003). Vascular Endothelial Growth Factor (VEGF), a 
molecule able to stimulate neo-angiogenesis, is localized on chromosome 6. 
VEGF has also a neuroprotective function stimulating the neuronal survival 
and the growth, regeneration and differentiation of axons. Moreover, VEGF 
levels were increased in the neurocortex of AD brains. A SNP in the 
promoter region at position -2578 (substitution C/A) in Italian population is 
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associated with an increased risk of developing AD, with an accelerated 
cognitive decline and an increased rate of progression from MCI to AD 
(Chiappelli M et al., 2006). 
Single SNPs are not very informative to predict the individual risk to 
develop AD. In fact, all these SNPs explain a little percentage of all cases of 
Alzheimer‟s disease, whereas the vast majority (especially for late-onset 
forms of the disease) have other, more complex genetic determinants 
(Campion D et al., 1999). 
More than 550 other genes have been proposed as candidates for 
Alzheimer‟s disease susceptibility, but thus far none has been confirmed to 
have a role in Alzheimer‟s disease pathogenesis (Gatz M. et al., 2006). 
In the last decades scientists, to understand the pathogenetic mechanisms 
leading to neurodegeneration and dementia, focused their study on one-two 
or few genes and on few SNPs. This approach, is very limiting because it 
attempts to explain a complex and multifactorial disease as Alzheimer with 
approximate methods. 
Recent genome-wide association approaches have delivered several 
additional AD susceptibility loci that are common in the general population. 
Genome-wide association (GWA) studies are best understood as an 
extension of candidate gene association studies, scaled up to cover hundreds 
of thousands of markers across the genome in samples usually from several 
thousand of cases and controls. 
The GWA approach allows the detection of much smaller effect sizes than 
the previous linkage-based genome-wide studies. 
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However, this sensitivity makes them vulnerable to false positive findings 
caused by subtle differences between cases and controls that may arise as a 
result of issues, such as genotyping errors, population stratification, and 
sample mix-ups as well as the more obvious issue of multiple testing. 
In 2009 a great number of GWA studies have been proposed to find strong 
association with AD (Beecham GW et al., 2009; Carrasquillo MM et al., 
2009; Lambert JC et al., 2009; Harold et al., 2009) 
The two large GWAS from the UK (Harold D et al., 2009) and France 
(Lambert JC et al., 2009) were published back-to-back highlighting three 
novel AD genes, i.e., CLU (clusterin; apolipoprotein J), CR1 (complement 
component (3b/4b) receptor 1), and PICALM (phosphatidylinositol binding 
clathrin assembly protein). These loci have since received overwhelming 
support from independent follow-up studies (Carrasquillo MM et al., 2010; 
Jun G et al., 2010) and currently rank at the very top of the AlzGene meta-
analyses, directly following APOE. In addition, there are several other SNPs 
in each of these loci showing highly significant association (p values < 1 × 
10
−5
) with AD risk, leaving essentially no doubt that variants in these or 
nearby genes represent genuine AD susceptibility loci. 
It is important to note, the risk effects exerted by the new GWA loci are 
small, i.e., they confer a mere 0.10-fold to 0.15-fold increase or decrease 
in AD risk in carriers versus non carriers of the associated alleles, compared 
to a nearly 4-fold increase in AD risk related to the presence of the APOE 
4 allele. 
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Gene-Gene interaction: epistasis 
In typical case-control association studies of complex diseases, candidate 
genes are examined individually, either evaluating one marker at a time or 
forming haplotypes over multiple neighbouring loci in and around one gene. 
These methods make the implicit assumption that susceptibility loci can be 
identified through their independent marginal contribution to the trait 
variability (Gambaro G et al., 2000). 
Critics have pointed out that findings from many genetic association studies 
were inconsistent, with many failures of replication (Ioannidis JPA et al., 
2001). 
It has been suggest that this lack of replication can be a “signature of 
epistasis” or a gene-gene interaction (Moore JH et al. 2005.; Wade MJ, 
2001). 
Epistasis was first described by Bateson (1909) as the effect of one gene 
masking (or literally standing upon) the effect of another. The Bateson view 
of epistasis has also been described as biological epistasis (Moore JH and 
Williams SM, 2005), where variation in the physical interaction of 
biomolecules affects a phenotype. From a statistical perspective, epistasis 
was also observed as multiallelic segregation patterns by Fisher (1918) who 
mathematically described the phenomenon as deviation from additivity in a 
linear model of genotypes. Statistical epistasis and biological epistasis 
eventually converge as scientific understanding progresses. 
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But the study of epistasis has suffered severly from the lack of appropriate 
statistical methods. Logistic regression analysis and methods based on it, 
such as synergy factor analysis, are best used only for the examination of 
binary interactions. Various methods have been proposed for the study of 
higher order interactions, but several suffer from problems of interpretation. 
Therefore, methods for the formal analysis of complex gene-gene 
interactions and gene-protein interaction remain an open question. 
For Alzheimer‟s disease two different new epistasis approaches have been 
proposed in these last years: the use of Grade of Membership (GoM) 
method and the Artificial Neuronal Network (ANN). 
These two new statistical models have the potential of analyzing the 
relationship between factors and disease and the degree of interaction of all 
factors together and with the disease. 
Grade of Membership (GoM) 
The increasing amount of clinical, genetic, and phenotypic data of 
multifactorial diseases such AD, requires specific tools able to gather and 
recompose this information. These tools are not easily available today as the 
traditional statistical reductionistic approach tends to „see‟ things 
individually, to simplify, and to look at one single element at a time. 
Grade of Membership analysis identifes typologies or set group in rich 
datasets represented by profiles of response frequencies for the variables 
(Manton et al., 1991; Manton et al., 1992) 
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This approach has identified sufficient genetic risk sets for Alzheimer‟s 
disease (Corder EH et al.2006), vulnerable and robust sets of gene variants 
in mitochondrial complex I in Parkinson‟s disease (Corder EH et al.,2006), 
and multilocus genotypes specific to breast cancer and fibroadenoma 
(Corder EH et al. 2006). 
Using GoM, the user specifies a number of latent groups, extreme pure type 
risk sets or profiles, to be identified. 
The GoM model likelihood can be described after first identifying some 
indices. One is the number of subjects I (i=1, 2, . . ., I). The second index is 
the number of variables J (j=1, 2, . . ., J). The third index is Lj: the set of 
response levels for the Jth variable. This leads to the definition of the basic 
GoM model where the probability that the ith subject has the Ljth level of 
the Jth variable is defined by a binary variable (i.e. yijl = 0, 1). 
The model with these definitions is 
k
kjlgikyijlprob )0.1(  where the 
gik are convexly constrained scores for subjects and the λkjl are probabilities 
that, for the Kth latent group, the Ljth level is found for the Jth variable. 
A recent paper showed the attempt to find independent risk groups including 
several genetic variant for cognitive decline and Alzheimer‟s disease using 
this fuzzy latent statistic (Licastro F et al., 2007). 
Licastro et al. identified four group representing the status and the genetic 
background: Set I represents low intrinsic risk: there is a low density of pro-
inflammatory gene variants at the investigated loci. Sets II, III, and IV 
represent sufficient risk sets for AD. 
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According to this model, each risk set is defined by probabilities for each 
outcome AD status, rate of cognitive decline age group and the various 
genotypes (IL10, IL6, HMGCR, APOE, ACT, INFg, TNF) found for the 
loci. 
At the same time, individuals are related to the groups via membership 
scores ranging from zero denoting no resemblance to the risk set to one, i.e. 
the individual matches the risk set exactly. The scores for highrisk sets were 
then input into logistic models to estimate the odds of AD and produce 95% 
CI. To evaluate each variable‟s information content, statistic „H‟ (Shannon, 
Bell Laboratories) was estimated for each variable. H is close to zero if each 
group has similar frequencies. Higher values denote increasing information 
content and differences in displayed frequencies from group to group. Here, 
the clinical status variables had the highest information content: H was 1.33 
for AD status/ age and 1.11 for rate of cognitive decline. IL-10 was the most 
informative genetic variable (H= 1.06), more informative than APOE 
genotype (H= 0.44). 
Artificial Neuronal Network (ANN) 
Classical statistics predictive models like discriminant analysis, logistic 
regression, etc., are able to utilize a number of factors simultaneously higher 
than a human mind. This number generally ranges between 8-15 variables. 
However, it is not unusual to have at hand, especially when faced with 
treatment planning for a chronic degenerative disorder, hundreds of 
different variables, consisting of clinical history data, objective findings, 
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symptomatology, multi-item scales of different meanings, laboratory 
examinations and imaging procedures. 
With the increased availability and use of functional genomics and digital 
imaging we now tentatively have at our disposition thousands of data per 
subject. More features imply more information and potentially higher 
accuracy. Unfortunately an important paradox is that more features we have, 
the more difficult information extraction is. 
A part from quantitative features, non linearity, complexity, fuzzy 
interaction are new emerging qualitative features of chronic degenerative 
diseases which account for most morbidity and mortality in western world. 
New statistical approaches, based on new mathematical and logic 
assumptions broadly belonging to artificial adaptive system family allow to 
tame these intractable data sets. 
Actually the coupling of computer science and these new theoretical bases 
coming from complex systems mathematics allows the creation of 
“intelligent” agents able to adapt themselves dynamically to problem of 
high complexity: the Artificial Adaptive Systems, which include Artificial 
Neural Networks( ANNs ) (Grossi E and Buscema M, 2007; Grossi E and 
Buscema M, 2006) 
ANNs are adaptive models for the analysis of data which are inspired by the 
functioning processes of the human brain (McCulloch WS et al., 1943). 
They are systems which are able to modify their internal structure in relation 
to a function objective. They are particularly suited for solving problems of 
the non linear type. ANNs are able to reconstruct the approximate rules that 
Introduction 
33 
 
put a certain set of data which describes the problem being considered - with 
a set of data which provides the solution. The base elements of the ANN are 
the nodes, also called processing elements (PE), and the connections. 
Each node has its own input, from which it receives communications from 
other nodes and/or from the environment and its own output, from which it 
communicates with other nodes or with the environment. Finally, each node 
has a function f through which it transforms its own global input into output. 
Each connection is characterized by the strength with which pairs of nodes 
are excited or inhibited. Positive values indicate excitatory connections, the 
negative ones inhibitory connections. 
The connections between the nodes can modify themselves over time. This 
dynamic starts a learning process in the entire ANN. The way through 
which the nodes modify themselves is called “Law of Learning”. 
The learning process is, therefore, one of the key mechanisms that 
characterize the ANN, which are considered adaptive processing systems. 
The learning process is one way to adapt the connections of an ANN to the 
data structure that makes up the environment and, therefore, a way to 
“understand” the data base itself and its internal relations (Rumelhart DE et 
al., 1986; Personnaz L et al., 1986). 
In summary, the aim of the “analyzer” is not to analyze the language of each 
individual variable, but to evaluate the meta-language which considers the 
holistic contribution of all the recorded variables (Grossi E, 2010). 
Artificial Adaptive Systems and in particular Neural Networks are already 
emerging as new tools in medical statistics ranging from heart diseases, 
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gastroenterology and neurology with special regard to Alzheimer disease, 
stroke and Amyotrophic Lateral Sclerosis (Penco S et al., 2008; Rossini PM 
et al., 2008; Licastro F et al., 2010; Grossi E, 2006). 
In conclusion, data mining by ANN could show a non linear relationship 
between genetic and environmental variables and show a connectivity map 
among a high number of variables. This approach may be today very useful 
to understand the complex mechanisms of multifactorial disease as AD. 
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Elevated plasma levels of α-1-antichymotrypsin 
in age-related cognitive decline and Alzheimer’s 
disease: a potential therapeutic target 
Alzheimer‟s Disease (AD) is a chronic neurodegenerative disorder and the 
clinical disease develops when the neuronal loss is already advanced. The 
clinical diagnosis of AD is performed by excluding other forms of dementia 
and formal diagnosis is done only post mortem after the identification of 
senile plaques. Amyloid deposit consists in extracellular deposition of beta 
amyloid protein and neurofibrillary tangles consists of intracellular 
aggregates of tau. Microglia and astrocites surrounding brain areas with 
neurodegeneration showed activated phenotypes and expressed 
inflammatory molecules and several of these molecules are found in brains 
of patients affected by AD and associated with senile plaques. 
Many studies support the hypothesis that the inflammation plays a pivotal 
role in AD since the routine use of non-steroid anti-inflammatory drugs was 
associated with a decreased incidence of AD. Alpha 1 antichymotrypsin 
(ACT) is a serum acute phase glycoprotein belonging to the Serin Protease 
Inhibitor family called SERPIN. ACT is mainly produced by the liver, but is 
also widely distributed in the central nervous system. In the brain, ACT is 
produced by astrocytes and it is a secondary component of senile plaques in 
the AD brain (Abraham CR, 2001). It has been proposed that ACT and 
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APOE co-localized with Abeta amyloid plaques. Moreover, in animal 
model, ACT and also APOE, affected amyloid deposition and cognitive 
performances. ACT plasma levels have been correlated by many authors 
with the cognitive decline and dementia therefore data emerging from the 
association of ACT levels and the developing of AD are conflicting: some 
studies reported high serum ACT levels in AD patients (Licastro F et al., 
1995; Licastro F et al., 2000) while other showed normal ACT values 
(Furby A et al., 1991; Lanzrein AS et al., 1998) 
In this work we proposed a new method to measure ACT plasma levels in a 
large cohort of cognitively healthy subjects, in subjects with cognitive 
impairment but not dementia (CIND) and two different AD populations 
(mild and severe AD). 
Circulating levels of ACT were higher in patients with mild or severe AD 
than in CIND or in controls. 
We found also an age dependent increase of ACT levels: the oldest elderly 
showed higher ACT levels than younger. In a previously paper (Licastro et 
al., 2005) we demonstrated that a polymorphism in the promoter region at 
position -51 was associated to AD and to the rate of cognitive deterioration. 
Patients with mild AD were also followed up for 2 years and the cognitive 
performances were monitored. MMSE score were recorded and patients 
were stratified according to the rate of cognitive decline as described by 
Doody (Doody RS, 2001). ACT levels were higher in AD patients with fast 
cognitive deterioration than those in patients with an intermediate or a slow 
decline. A small group of CIND were also monitored for 4 years. ACT 
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levels were, once again, higher in CIND subjects that developed dementia 
then in those who did not developed AD. These association was also 
showed in APOE e4 carrier subjects. 
Our data confirm that high ACT levels were associated with Alzheimer‟s 
disease and with the rate cognitive decline. 
We reinforce also the hypothesis that the association APOE and ACT play a 
pivotal role in AD and in its the clinical progression. 
General discussion 
132 
 
Multivariable network associated with 
cognitive decline and dementia 
AD is a multifactorial complex disease and several risk factors may 
differentially contribute to the clinical history of the disease, therefore 
powerful statistically algorithm are needed to evaluate interactions among 
variables and their association with the pathogenetic mechanisms involved 
in the disease. 
We just discussed the importance of the epistasis in complex disease like 
AD where genetic and environmental factors interact to lead to 
neuropathological features typical of AD. Genetic studies try to explain the 
complexity of this disease but with poor results since the use of classical 
statistical methods does not allow to combine a large number of variables of 
different nature. 
The use of Artificial Neuronal Network (ANN) might be very useful to 
understand how the interaction between genetic and phenotipic variables 
could be associated to Alzhimer‟s disease and cognitive decline. 
ANNs could be used to find connection between variables that normally are 
hidden or normally difficult to find. This approach aims to create a semantic 
connectivity map in which non linear association were preserved, 
connections schemes are explicit and the complex dynamics of adaptive 
interactions is captured. 
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The final graphic results is a map with all the variable connected and with 
some aggregation points called hubs that represent the convergence point of 
group of variables. 
For these reasons we applied this new statistical method to analyzed the 
database generate during the Conselice Study of Brain Aging. 
This study is a population-based prospective investigation focused on an 
homogeneous elderly population from Northern Italy (Ravaglia G et al., 
2001). 
The principal aim of this investigation was to explore environmental, 
epidemiological, genetic and phenotypic risk factors for dementia in the 
elderly. 
The study start in 1999 where about 1200 elderly 65 years old or older, 
living in Conselice a little county in northern Italy were enrolled. All 
participants were interviewed and underwent medical examination for 
cognitive evaluation. A blood sample and a computerized radiogram scan of 
the brain from each subject was taken. After 5 years subjects underwent to 
medical and cognitive re-evaluation years subjects underwent medical and 
cognitive re-evaluation and 937 elderly completed the follow-up. (Ravaglia, 
G et al. 2001.). 
From this study a biological and clinical database during the 5-year follow-
up has been generated and biological markers have been found individually 
associated with the AD risk, cognitive decline and incident AD (Ravaglia G 
et al., 2006; Ravaglia G et al., 2007a; Ravaglia G et al., 2007b). 
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Here we showed very interesting results from the application of this ANNs 
statistical methods regarding 35 different variables (both genetic, 
phenotypic and environmental) in the Conselice Study. 
In this article data recording during the follow up allowed to build a map 
where three major biological hubs connected variables with the three 
different cognitive conditions: no cognitive decline, CIND and dementia 
were identified. 
The three hubs have been identified in hydroxyl-methyl-gutaryl-CoA 
reductase enzyme (HMGCR), plasma cholesterol levels and age. 
Related dependent variables converge to these hubs, that in turn are 
considered as relevant biological variables in the connectivity map. 
Among variables, several gene variants of different inflammatory genes and 
the plasma levels of their cognate phenotypic factors showed a variable 
degree of relevance to brain aging and development of dementia. 
Everyone knows that age is a risk factor for AD in fact it is important to 
keep in mind that AD is the main pathological disease associated with 
ageing. being less than 5% of AD cases affect people under the age of 65 
years. 
HMGCR is the rate limiting enzyme in cholesterol synthesis and controls 
cholesterol availability by affecting the synthesis of mevalonate and 
isoprenoid compounds which are necessary for the attachment of several 
proteins to biological membranes (Zhang FL and Casey PJ, 1996). HMGCR 
genotype has been recently described as a genetic risk factor for AD and 
affect the rate of cognitive decline in AD patients (Porcellini et al., 2007). 
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Our data from The Conselice Study confirmed that this enzyme was a 
relevant factor for the developing of dementia. 
This enzyme is also very important since it is the molecular target for statins 
and for this HMGCR enzyme could be pharmacological target for AD 
prevention. 
In fact, data regarding the possible preventive effect of statins in AD were 
on record (Jick H et al., 2000), although another investigation did not 
confirm these observations (Rea TD et al.,2005). 
There was a strong linkage of the HMGCR genotype hub with the second 
hub, i.e. serum cholesterol. There are many evidences showing that 
cholesterol is associated to Alzheimer‟s disease. Moreover the most 
common risk factor for AD is the Apolipoprotein E, the main cholesterol 
transporter in the brain. In our map also a link of other lipidic variables with 
cholesterol and AD is shown. 
In conclusion, the connectivity map presented here on incident dementia 
extended previous observations from case/control investigations and 
confirmed that some immune factors could indeed play a role in the 
pathogenesis of age associated dementia. Our findings also showed a new 
link between immunity, cholesterol metabolism and age in relation with 
cognitive deterioration. 
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Genome-wide association study identifies 
variants at CLU and CR1 associated with 
Alzheimer’s disease 
Three decades of genetic research in Alzheimer disease (AD) have 
substantially broadened our understanding of the pathogenetic mechanisms 
leading to neurodegeneration and dementia. 
Genetic studies have led to the consistent identification of the ε4 allele of 
APOE as a susceptibility locus for late-onset Alzheimer‟s disease. Twin 
studies suggest that genes may have a role in more than 60% of Alzheimer‟s 
disease susceptibility (Gatz M. et al., 2006.) and that APOE may account for 
as much as 50% of this genetic susceptibility (Ashford JW. and Mortimer 
JA, 2002). 
More than 550 other genes have been proposed as candidates for 
Alzheimer‟s disease susceptibility, but thus far none have been consistently 
confirmed to have a role in Alzheimer‟s disease pathogenesis (Bertram L et 
al., 2007). 
To identify other risk loci, we conducted first a large genome-wide 
association study of 2,032 individuals from France with Alzheimer‟s disease 
(cases) and 5,328 controls. 
Then, the study was extended to AD and control samples from Belgium, 
Finland, Italy and Spain (AD cases 3,978 and 3,297 controls). 
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In this GWA about 500.000 SNPs have been analyzed by a new generation 
sequencing in AD and control samples. 
As expected, APOE ε4 resulted associated to AD. Moreover other two loci 
showed a strong association with AD (p=9x10
-8
). The first of these loci 
encompasses CLU on 8p21-p12, and the second spans the gene encoding 
complement component (3b/4b) receptor 1 (CR1) on 1q32. 
CLU also called APOJ, like APOE is the most abundantly expressed 
apolipoproteins in the central nervous system (Roheim PS et al., 1979; May 
PC & Finch CE, 1992), with strong analogies in terms of possible impact on 
the AD physiopathological process. Like APOE, CLU is present in amyloid 
plaques (May PC. et al., 1990; Calero M. et al., 2000) and can bind Aβ 
(Ghiso J et al., 1993. ; Zlokovic BV. et al.. 1996) 
In the CLU gene three SNPs (rs2279590, rs11136000, rs9331888) showed 
statistically significant association with Alzheimer‟s disease in both stages 
of the study. The marker that showed the highest association was CLU rs 
11136000 with an OR for the minor allele of 0.86 (95% CI 0.81–0.90, P = 
7.5 × 10−9). We detected a statistical interaction between the APOE ε4 
status and the CLU SNPs. For rs11136000, although the association was 
significant in both ε4 carriers and non-carriers, it was more significant in 
APOE ε4 carriers. 
Then, a linkage disequilibrium test was applied to these three SNPs to 
investigate if certain CLU haplotypes could be correlated to AD. We found 
three common haplotypes (TTC, CCC and CCG) all associated with a 
statistically significant increased disease risk. 
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The other locus associated to AD emerging from this GWA study was CR1. 
CR1 is the main receptor that binds the complement protein C3b; plays an 
important role in the removal of immune complexes coated with C3b and 
C4b. It also regulates the complement cascade activation by preventing 
formation of classical and alternative pathway convertases. 
Several observations suggest that pathways involving C3b and CR1 are 
involved in the Alzheimer‟s disease process, particularly in Aβ clearance. 
According to this, APP transgenic mice with an inhibition or deficiency of 
C3 display increased Aβ accumulation and neurodegeneration (Wyss-Coray 
T et al., 2002) 
Like in CLU, also in CR we found SNPs that seems to be associated to AD: 
rs6656401 with an OR of 1.21 (p<10
-9
) and rs3818361 with an OR of 
1.19(p<10
-8
); this association was also confirmed in APOE 4 carriers. 
Also in CR1 we identified three possible haplotypes correlated to the risk of 
Alzheimer‟s disease (GG, GA and AA). 
The odds ratio was highest for the AA haplotype compared to the GG 
haplotype. 
In addition to the previously known APOE locus, we have identified loci at 
CLU and CR1 that are potentially associated with the risk of late-onset 
Alzheimer‟s disease. Biological evidence suggests that the genes at these 
loci, along with APOE, are involved in Aβ clearance. These data may 
indicate that whereas familial early-onset forms of Alzheimer‟s disease are 
mainly linked to genes implicated in Aβ overproduction, genetic variants at 
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APOE and these newly defined loci may influence susceptibility to late-
onset forms of the disease as a result of roles in Aβ clearance. 
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Multi factorial interactions in the pathogenesis 
pathway of Alzheimer’s disease: a new risk 
charts for prevention of dementia 
Alzheimer's disease (AD) is the most common form of dementia. Severe 
memory loss, confusion, and impaired cognitive abilities characterize AD. 
Since a dramatic increase in mean life span and life expectant leading to a 
substantial increment of elderly population in West society, AD has also 
become a globally important health issue and the treatment of AD is a 
challenge for modern medicine. 
Neuropathological hallmarks of AD are extracellular amyloid deposits 
(neuritic plaques) and intracellular deposition of degenerate filaments 
(neurofibrillary tangles) (Selkoe DJ, 2001). 
The presence of these characteristic features are no sufficient to explain 
such a complexity of the disease. Other factors are then involved in the 
pathogenesis of AD like chronic inflammation and vascular damage. In fact, 
it has been demonstrated that all age related disease like Alzheimer have an 
important inflammatory component as an increased levels of circulating 
inflammatory mediators (Baggio G et al., 1998; Dumont Pet al., 2000) 
Genetic studies had also underlined the importance of specific genetic 
background leading to a probable risk to develop AD (Licastro et al., 2007; 
Chiappelli M et al., 2006; Licastro F et al., 2010) 
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In this article we showed a second application of the Artificial Neuronal 
Network (ANN) in the Conselice Database. The first one, as just described 
before, regarding 35 variable dataset, three main hubs were represented by 
HMGCR enzyme, plasma cholesterol levels and age. 
Here we extended the data set increasing the numbers of variables and 
adding prevalent AD, VD and CIND cases. In this new connectivity map we 
found four major biological hubs: 1) low blood cholesterol, 2) high BMI 
index, 3) low blood HDL, 4) low blood folate. 
Different genotypic, phenotypic, clinical, pharmacological or habit variables 
converged to these hubs or cluster of connectivity. Age was closely 
correlated to prevalent AD cases confirming that age is the major factor in 
AD pathogenesis. 
Variables as APOEε4 allele, increased Vit B12 and ACT levels, presence of 
mutated allele of several inflammatory genes were related to the main hubs 
underlining the implication of all these factors with the disease. 
As expected, cognitive healthy status, in the map, is far from AD, VD and 
CIND condition. 
Our findings showed four major connecting nodes from the Conselice data 
base; these hubs linked apparently different factors to cognitive impairment 
and dementia via cholesterol, cholesterol gene dependent pathway, BMI and 
age. A new association among different immunological factors and lipid 
metabolism with incident dementia has also emerged. 
With this article, we confirmed that some immune factors could play a role 
in the pathogenesis of age-associated dementia by modifying metabolic and 
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lipid variables and also show a new link between immunity, cholesterol 
metabolism and age related cognitive deterioration. 
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Altered glycosylation profile of purified plasma 
ACT from Alzheimer’s disease 
As we just described before, the main pathological features of AD are the 
presence of extracellular senile plaques formed of β amyloid peptide and the 
presence of intracellular deposition of neurofibrillary tangles. 
ACT, an inflammatory glycoprotein may be involved in the pathogenesis of 
Alzheimer‟s disease. In fact, it has been suggested that ACT binds Ab 
peptide and affects the rate of amyloid fibril formation in vitro (Eriksson S 
et al., 1995; Fraser PE et al., 1993) and it has been also shown to influence 
TAU protein phosphorylation and apoptosis in neuronal cells (Padmanabhan 
J et al., 2006). 
ACT levels have been associated to AD and to cognitive decline. However, 
conflicting results are on record. Different techniques for ACT detection, 
different criteria for the selection of controls and AD patients or small 
numbers of cases and controls included in the studies may account for 
contradictory results regarding the association of abnormal ACT plasma 
levels with AD. 
Moreover, alterations in molecular forms of ACT present in tissues and/or 
blood might also account for increased variability of ACT detection in AD 
and controls. 
In this paper we focused our attention to the different molecular form of 
ACT in AD patients and controls. 
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Inflammatory states are usually associated with changes in the glycosylation 
pattern of acute phase proteins like ACT (Chavan MM et al., 2005; Gornik 
O and Lauc G, 2008). 
ACT in fact is a glycoprotein composed mainly by six N-glycosylation sites 
and shows four oligosaccharide side-chains with disialyl diantennary and 
trisialyl triantennary type glycan structures with traces of disialylated 
triantennary oligosaccharides. 
Many disease as myocardial infarction and some kind of cancers, are 
correlated to changes in sugar content of ACT protein, but no studies on 
plasma ACT glycosylation patterns in AD are on record. 
In AD altered glycosilation pattern of presenilin-1, a molecule forming the 
catalytic core of the -secretase complex and able to generate amyloidogenic 
peptides (Farquhar MJ et al., 2003) and an abnormal glycosylation of reelin, 
a glycoprotein essential for the correct cyto-architectonic organization of the 
developing CNS, were previously shown (Botella-Lopez A et al., 2008). 
Here we show results on different glycosilation pattern of ACT protein in 
AD patients and controls. 
ACT blood levels were measured as previously described with some 
modifications (Porcellini et al., 2008), ACT was performed by affinity 
chromatography using Hitrap NHS-activated HP columns and the glycan 
profile of purified ACT samples was obtained by using the Qiagen 
Qproteome™ GlycoArray. 
From Western Blot analysis we showed that ACT resulted in three bands 
both in AD patient and in controls. 
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On the contrary, when PNGase F treatments was performed on denatured 
purified ACT, four bands were detected in controls, whereas ACT from AD 
samples resolved again into three bands showing differences in protein 
composition between two groups of samples after denaturation. 
As we just said, glycosylation is a versatile biochemical mechanism and 
changing in sugar chains composition could be strongly associated to 
several diseases including AD. 
For this reason we further analyzed the sugar composition of purified ACT 
from controls and AD samples using an Array technique. This kit allowed to 
evaluate different glycan epitopes on ACT protein: Bi Antennary, Tri/Tetra 
Antennary, High Mannose, Sialic Acid, Terminal GlcNAc, Terminal 
GalNAc, Bisecting GlcNAc and O-Glycans. 
The analysis of the results obtained from the scan of the array produced a 
detailed profile of ACT glycosylation status and a glycan epitope prediction 
pattern. 
This analysis resulted in a partially different pattern of glycan profiles 
between ACT from AD and controls; sialic acid content being different 
between AD and CTR. 
AD samples were further stratified in to two groups called AD 1 and AD 2 
according to the differential rate of cognitive decline in a two years of 
follow up. Differences were found in GlcNac residues between AD 1 and 
AD 2 group where AD 1 showed a faster cognitive deterioration than AD 2. 
In conclusion, in this article we confirm that ACT is a protein involved in 
Alzheimer‟s disease and in the cognitive impairment. Moreover, our 
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findings suggest that low content of terminal GlcNac glycans and sialic acid 
in peripheral ACT might be a marker of diseases progression and it might be 
used in clinical trials as surrogate marker of clinical efficacy. 
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The CALHM1 P86L Polymorphism is a 
Genetic Modifier of Age at Onset in 
Alzheimer's Disease: a Meta-Analysis Study 
Although Alzheimer's disease (AD) is the most common cause of dementia 
in the elderly, its etiology is still not fully understood. The characterization 
of causative factors is thus important for better defining the patho-
physiological processes involved. 
Although the importance of the genetic component of these non-Mendelian 
forms of dementia has long been debated, there is now a large body of 
evidence suggesting that genetic variations play a major role in determining 
risk for this form of AD as well. 
Recently, a novel gene on chromosome 10 (10q24.33) was reported to 
modulate the risk for late-onset sporadic AD (Dreses-Werringloer U et al., 
2008). In that study, several independent case-control cohorts were 
genotyped for a Pro to Leu alteration at codon 86 (P86L; rs2986017) in the 
gene for calcium homeostasis modulator-1 (CALHM1), a transmembrane 
glycoprotein. 
Perturbations in calcium homeostasis were observed in several 
neurodegenerative disorders including Alzheimer's disease. CALHM1 is a 
component of a novel cerebral calcium channel family involved in Aβ 
metabolism. The identification of CALHM1 as a key modulator of calcium 
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homeostasis and Aβ levels provides strong support for the calcium 
hypothesis of AD. 
Moreover, CALHM1 polymorphisms may influence AD risk even if some 
results are conflicting. 
Many studies in fact did not shown an association of P86L polymorphism 
with AD (Bertram L et al, 2009) whereas other studies found it (Boada M et 
al, 2010; Li H et al, 2008). 
Despite this contradictory data using cognitive status as phenotype, three 
studies showed association among an earlier age at onset (AAO) the 
homozygosity of the L allele and a marker in the CALHM1 vicinity (Minster 
RL et al., 2009; Boada M et al., 2010; Li H et al., 2008). 
In this article we presented a meta analysis on the CALHM1 P86L 
polymorphism conducted on 7.873 AD cases and 13.274 controls. 
Using both novel and previously published genotype data the P86L 
polymorphism in CALHM1 seems not to be associated to the risk of 
Alzheimer‟s disease. 
The discrepancy of risk effects between the independent follow-up data and 
the data first published by Dreses-Werringloer et al. (Dreses-Werringloer U 
et al, 2008), may indicates a false-positive finding in the initial report, a 
situation commonly observed in genetically complex diseases and referred 
to as “proteus phenomenon” or to as the “winner's curse phenomenon” 
(Kraft P, 2008). 
However, even though our meta-analysis results rather unequivocally refute 
the initial findings suggesting that CALHM1 is a genetic risk factor for AD, 
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the present work suggests that the CALHM1 P86L polymorphism could 
modulate AAO and more specifically the APOE ε4 allele's dose effect on 
this phenotype. 
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Alzheimer's disease gene signature says: 
beware of brain viral infections 
AD represents one of the most important cause of disability in the elderly 
and therefore one of the major age associated health and social problem. 
As above reported, AD is a chronic neurodegenerative disorder clinically 
merging when the progressive neuronal death is in an advanced state and up 
to date no effective medication is available. Unfortunately, AD is still a non 
curable human disorder. 
Several experimental findings showed that in the non familial form of the 
disease representing over 95% of cases genetic factors might be involved in 
the disease. A recent of genome wide association (GWA) study conducted 
by many European research laboratories on 5000 patients and 7000 controls 
reported that the allele 4 of APOE gene and single nucleotide polymorphism 
(SNP) in other genes regulating inflammation pathways were strongly 
associated with AD. 
It can not be excluded that environmental factors may also contribute to 
brain inflammation and degeneration associated to AD. In particular, some 
initial observations indicated that the DNA of Herpes simplex virus type 1 
(HSV-1) was found more frequently in the cerebral cortex of patients with 
AD than non-demented controls (Itzhaki RF et al., 1997). 
The presence of viral DNA was particularly frequent in AD patients 
carrying the allele e4 of APOE gene. 
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In the recent GWA by Lambert et al. (Lambert et al., 2009) the gene CLU 
and CR1 have been strongly correlated to AD with a very low association 
probability (p<10
-10
). Moreover, in this report, also a limited number of 
genes were highly associated (p > l0-5) with the disease. 
In this article we hypothesized that a gene cluster may predispose to AD via 
complex and diverse mechanisms each contributing to an increase of 
individual susceptibility to brain viral infections. 
The first set of genes was located in close vicinity of the APOE locus on the 
chromosome 19 and consisted of the poliovirus receptor-related 2, APOE 
gene, the translocase of outer mitochondrial membrane 40 homolog 
(TOMM-40), the glycoprotein carcinoembryonic antigen related cell 
adhesion molecule-l6 (CEACAM-l 6) and B-cell/lymphoma-3 (Bcl-3) 
genes. Genes in the second set were located on different chromosomes: 
CLU on chromosome 8; CRl, and C-type lectin domain family 16 member 
A (CLEC-16A) on chromosome 16. 
All this gene, as reported in the paper, are linked to different herpes simplex 
viral mechanisms and we argue that the concomitant presence of several 
polymorphisms of these genes in the same individual might represent a 
genetic signature of AD 
Such hypothesis discussed here, where individual susceptibility to pathogen 
infection of the brain, particularly HSV and related viruses seems to be 
associated to Alzheimer‟s disease, is supported also by other different 
papers (Itzhaki RF et al., 2008; Carter CJ, 2008; Wozniak MA et al., 2009). 
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In fact brain infection by reactivated latent viruses might be one of the 
primus movens inducing progressive neuronal loss, astro-glia activation, 
and, impaired APP transport along the axons. 
In conclusion, present findings suggest that during ageing virus reactivation 
may be more frequent in the elderly showing a genetic signature 
predisposing to an increased susceptibility for HSV and other virus 
infections of the brain. In these subjects the microorganisms are more likely 
to induce a limited, segmental and chronic sub-clinical pseudo-encephalitis 
resulting in a progressive neurodegeneration. 
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Sharing pathogenetic mechanisms between 
acute myocardial infarction and alzheimer’s 
disease as shown by partially ovelapping of 
gene variant profiles 
Alzheimer‟s disease (AD) is the most frequent form of dementia in the 
elderly (Nussbaum MD and Christopher E, 2003) characterized by a loss of 
neuronal synapses, deposits neuritic plaques and formation of 
neurofibrillary tangles (Katzman RN, 1996). Increasing levels of cytokines 
have been associated to dementia (Schmidt R et al., 2002; Licastro F and 
Chiappelli M, 2003; Shepherd CE et al., 2005) such as a large number of 
genetic variants (like single nucleotide polymorphism-SNPs) regulating 
inflammatory pathways or cholesterol methabolism (Licastro F et al., 2005; 
Corder EH et al., 1993; Grimaldi LM et al., 2000). 
Cardiovascular disorders and mainly Myocardial Infarction (AMI) are the 
leading causes of morbidity and mortality in modern western societies. 
(Weir RA et al., 2006; Gupta R and Kaufman S, 2006). 
The classical risk factor for these disease are: high cholesterol levels, 
hypertension, positive history of smoking, diabetes, obesity or sedentary life 
style. Unfortunately , more than half of patients with myocardial infarction 
do not demonstrate classical risk factors (Braunwald E, 1997). 
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Like in AD, many polymorphisms with functional relevance in the 
expression of inflammatory gene are often found at elevated frequency 
among patients with AMI (Lio D et al., 2004; Licastro F et al., 2002). 
No attempt has been made to evaluate whether specific immune genetic risk 
factors might constitute an important etiologic and pathogenetic link 
between AD and AMI. 
In this paper, we applied a relatively novel data analytic approach, namely, 
grade-of membership analysis (GoM) an alternative statistical approach to 
connect a large number of variables. 
The study presented integrates information on a panel of gene variants that 
modulate inflammation and cholesterol synthesis (IL10 -1082G/A, IL6 -
174G/C, TNF -308G/AIFNG +874T/A, SERPINA3 -51G/T, HMGCR -
911C/A, APOE 2/3/4) investigated among AMI, patients with AD and 
healthy controls, in order to directly look for hypothetical over-lapping 
and/or distinct genetic profiles. 
This methods allow to integrate information identifying low and high 
intrinsic risk sets which defined strong gradients of risk for individuals. 
We applied GoM to our dataset to verify if groups of variables (genetic 
variations in this case) could be associated to controls, AD, or AMI. 
Six genetic risk sets (I to VI) were identified by fuzzy latent classification. 
In the first group we localized mainly controls. In this group all the alleles 
are present in wild form (excepted for ACT -51 ). 
Sets II & III were at low risk before age 65. These sets lacked pro-
inflammatory alleles for HMGCR, TNF & APOE. The high risk sets IV to 
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VI included pro-inflammatory alleles for IL10 + IFNG + SERPINA3. 
Disease outcome and onset ages were influenced by the co-occurrence of 
HMGCR (IV, AD or AMI), TNF+ IL6 (V, AMI) or APOE (VI, AD or 
AMI). Close resemblance to one of the high risk sets, or the high risk sets 
taken together, denoted very high risk for AMI and/or AD. 
The partial overlapping of the genetic risk profile between AMI and AD 
describes an emerging picture showing that an abnormal regulation of 
inflammation is implicated in the pathogenesis of atherosclerosis and its 
complications and neurodegenerative processes leading to AD. 
In conclusion, data presented in this article, represent an approach to define 
individual risk profiles that may be applied to healthy subjects of different 
ages to predict intrinsic risk of AMI or AD. These risk profiles might then 
be used to define further diagnostic procedures which might indicate 
specific early therapeutic interventions, like statins and anti inflammatory 
drugs, aimed at prevention or significantly delay of the clinical 
manifestations of these two diseases. Finally, these findings may contribute 
to the goals of predictive diagnostics and personalized medicine. 
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AD is the most common neurodegenerative disease and one of the most 
common diseases in the industrialized world. 
Clinically AD is defined as a slowly progressing loss of cognitive functions, 
altered behavior, loss of social appropriateness and a progressive decline in 
language function ultimately leading to dementia and death. 
In Italy, AD affected subjects are between 800.000 and 1 million and 
unfortunately the number of new cases/year (incidence) is going to 
dramatically increase as a consequence of the progressive increase of the 
mean age and life expectancy in our population 
Neuropathologically, AD is characterized by the aggregation and deposition 
of mis-folded proteins, in particular aggregated b-amyloid (Ab) peptide in 
the form of extracellular senile (or neuritic) plaques, and 
hyperphosphorlylated tau protein in the form of intracellular neurofibrillary 
tangles (NFTs). 
These neuropathological hallmarks are often accompanied by abundant 
microvascular damage, including vascular amyloid deposits, and 
pronounced inflammation of the affected brain regions. 
Moreover, microglia and astrocytes surrounding brain areas with neuro-
degeneration showed activated phenotypes and expressed inflammatory 
molecules, and several of these molecules are found associated with senile 
plaques in brains of patients affected by AD (Chiappelli M et al., 2006). The 
presence of these kind of molecules and the presence of an activated 
phenotype confirms that inflammation plays a pivotal role in AD. This 
notion is also reinforced by the hypothesis that the routine use of non-
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steroid anti-inflammatory drugs was associated with a decreased incidence 
of AD (Breitner JC et al., 1994; Cohen HJ et al., 2003). 
Alzheimer‟s disease is a very complex and multifactorial disease where 
clinical factor as inflammation, pathogens infections, environmental factors 
and genetics underlines the pathogenesis of the disease. 
AD is commonly divided in two forms: one sporadic AD that involve about 
the 99% of cases and familial AD with an age of onset before 65 years 
(approximately 0.5% of cases) where autosomal dominant mutations in the 
APP, PSEN1 or PSEN2 genes are present. 
Several genetic studies have shown that the presence of apolipoprotein E e4, 
the main carrier of cholesterol in the brain was associated with an increased 
risk of developing late-onset AD (Corder EH, 1994). 
More than 550 other genes have been proposed as candidates for 
Alzheimer‟s disease susceptibility, but thus far none have been confirmed to 
have a role in Alzheimer‟s disease pathogenesis (Gatz M. et al., 2006). 
Two studies of Genome Wide Association (GWA) were recently published 
in Nature Genetics (Lambert JC et al., 2009; Hardold D et al.. 2009), in 
which independent groups have studied thousands of patients with AD and 
control subjects with the aim of identifying a set of single nucleotide 
polymorphisms (SNPs) associated with AD. 
In this thesis we investigated several aspects of Alzheimer focusing mainly 
on the genetic aspect of the disease. 
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The first approach that we applied was to analyze a single protein involved 
in inflammatory pathway and verify if this protein and its levels were 
associated to the pathogenesis of AD. 
In a large cohort of cognitively healthy subjects, in subjects with cognitive 
impairment and in two independent AD populations we confirmed that 
Alpha 1 antichymotrypsin (ACT), an acute phase protein, was associated to 
AD subjects, being ACT plasma levels higher in AD cases than controls. 
Moreover ACT protein from AD showed different glycosylation pathway. 
Even if these genetic studies gave positive results, this kind of approach is 
unfortunately very limited, since it is unlikely that a single genetic or 
phenotypic biomarkers may provide sufficient information for the potential 
risk of such a complex disease as dementia. 
The usual approach of focusing on one or a few candidate genes or one or 
few SNPs limits our ability to identify novel genetic factors associated with 
disease. 
Genome-wide association studies have been proposed as a solution to these 
problems: by new sequencing, technologies and microarray platform, in fact 
it is now possible analyze a large number of genes and SNPs in thousand of 
samples. 
Here we presented a GWA study where about 500.000 SNPs have been 
analyzed in 5.800 AD patients and 8.500 healthy controls. 
In this paper we demonstrated that two different gene, Clusterin and 
Complement receptor 1 were strongly associated to AD, independently to 
APOE ε4 allele. 
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Another gene found associated to AD is CALHM1: we found a significant 
association between the P86L L-allele and earlier onset for AD, particularly 
in carriers of the APOE ε4-allele. 
My studies presented in this thesis showed several biological markers 
individually associated with AD risk and cognitive decline, but results could 
not be conclusive or completely satisfactory because of the limited power of 
classical statistical analysis used. 
The goal should be to created a network of genetic, phenotypic and clinical 
data that allows to combine different type of variables. 
To analyze many variables in a large population are necessary statistical 
models capable of analyzing the relationship between factors and disease 
and the degree of interaction of all these factors together and with the 
disease. 
We used a new algorithm, the ANNs, aimed to map variables and search for 
connectivity. This method is based on an artificial adaptive system able to 
define the association strength of each variable with all the others in 
database, named the Auto Contractive Map (AutoCM). 
AutoCM generates a map of main connections between and among 
variables and the principal hubs of the system. These hubs can also be 
defined as variables with the maximum amount of connections in the map. 
In this new method non-linear associations were preserved, explicit 
connection schemes were investigated and the complexity of dynamic 
interactions were preserved. 
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We tested this new approach using Conselice database and we found 
specific variables associated to AD like cholesterol levels, the presence of 
variation in HMGCR enzyme and the age underlining the importance of 
cholesterol in the pathogenesis of the disease. 
A second application of ANNs was tested to an extended dataset in which 
other clinical and phenotypical variables were added. New factors such as 
the BMI, the amount of HDL and blood folate levels were associated to AD. 
We just strussed the complexity of Alzheimer‟s underlining the importance 
of the interaction between genetic and environmental factors. 
Pathogen infections, above all viral infections, have been previously 
associated to the pathogenesis of AD (Sequiera LW et al., 1979). 
The hypothesis suggests that virus and in particular herpes virus could enter 
the brain when an individual becomes older, perhaps because of a decline in 
the immune system. Brain invasion by virus triggers various mechanisms 
that lead to AD. 
Based on GWA results published on Nature Genetics, (Lambert et al., 2009) 
we suggest that a genetic cluster on chromosome 19, close by to the 
APOE gene, was strongly associated with AD. 
All these genes are involved in the entry and/or in the replication of herpes 
simplex viruses, in the cell-to cell virus spreading and also in the host 
immune resistance to virus infection. 
Our new hypothesis is that the presence of allelic polymorphisms in these 
genes results in a genetic signature that might affect individual brain 
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susceptibility to infection by herpes virus family during aging, leading to 
neuronal loss, inflammation and amyloid deposition. 
This thesis presents data on emerging disease that affects more and more 
people in all industrialized and developing countries and is becoming an 
important social and economic problem. 
Unfortunately there are no effective therapies for this disease and for this 
reason it is important to find new strategies for early intervention in the age-
associated cognitive decline and the prevention of the occurrence of clinical 
AD. 
If Alzheimer‟s disease is the main type of dementia, cardiovascular 
disorders are the leading causes of morbidity and mortality in modern 
western societies. 
With an epistatic statistical approach, we identified a partial overlapping 
multi-gene risk profiles associated to Acute myocardial infarction (AMI) 
and AD. This overlapping describes an emerging picture showing that an 
abnormal regulation of inflammation is implicated in the pathogenesis of 
atherosclerosis and its complications and neurodegenerative processes 
leading to AD (Licastro et al., 2010). 
These risk profiles might then be used to define further diagnostic 
procedures which might indicate specific early therapeutic interventions, 
like statins and anti inflammatory drugs, aimed at prevention or significantly 
delay of the clinical manifestations of these two diseases. Finally, these 
findings may contribute to the goals of predictive diagnostics and 
personalized medicine. 
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The epistatic approach suggested here, might help us to identify unaffected 
subjects with high risk of developing AD to be selected for early 
intervention trials focused on the prevention of cognitive decline and 
dementia. 
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